Quote | Prelude Therapeutics Incorporated (NASDAQ:PRLD)
Last: | $4.07 |
---|---|
Change Percent: | -0.25% |
Open: | $4.05 |
Close: | $4.07 |
High: | $4.07 |
Low: | $3.99 |
Volume: | 18,543 |
Last Trade Date Time: | 04/26/2024 03:00:00 am |
News | Prelude Therapeutics Incorporated (NASDAQ:PRLD)
Highly selective oral SMARCA2 degrader, PRT7732, shows robust anti-tumor activity in vivo as monotherapy and in combination with chemotherapy, at well-tolerated doses Potentially best-in-class CDK9 inhibitor, PRT2527, in Phase 1 development, is highly effective in preclinical hematolo...
WILMINGTON, Del., March 05, 2024 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that three posters with preclinical data on the Company’s highly selective oral SMARCA2 degrader, its potentially best-in-...
Message Board Posts | Prelude Therapeutics Incorporated (NASDAQ:PRLD)
Subject | By | Source | When |
---|---|---|---|
$PRLD just the news we needed | Termite7 | investorshub | 04/25/2023 2:00:41 AM |
Do we have a winner?Turn around time? | Termite7 | investorshub | 04/24/2023 9:58:06 AM |
$PRLD where is the squeeze? | Termite7 | investorshub | 04/19/2023 8:50:44 AM |
$PRLD The gaining | Termite7 | investorshub | 04/18/2023 2:07:54 AM |
YES!!!!! .....GET 'EM!!!!!!! | Termite7 | investorshub | 10/07/2021 2:44:44 PM |
News, Short Squeeze, Breakout and More Instantly...
Prelude Therapeutics Incorporated Company Name:
PRLD Stock Symbol:
NASDAQ Market:
Highly selective oral SMARCA2 degrader, PRT7732, shows robust anti-tumor activity in vivo as monotherapy and in combination with chemotherapy, at ...
Highly selective oral SMARCA2 degrader, PRT7732, shows robust anti-tumor activity in vivo as monotherapy and in combination with chemotherapy, at well-tolerated doses Potentially best-in-class CDK9 inhibitor, PRT2527, in Phase 1 development, is highly effective in preclinical hematolo...
WILMINGTON, Del., March 05, 2024 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (NASDAQ:PRLD), a clinical-stage precision oncology compan...